Annual Report 2024
A challenging fiscal year for the Eppendorf Group
2024 was one of the most challenging fiscal years in Eppendorf’s history, demanding a great deal from the global team and putting all of the company’s employees under much strain. The year was characterized by harsh economic conditions, geopolitical crises and steep price increases along the entire value chain.
The Eppendorf Group recorded consolidated revenue of €980.3 million in the reporting year (prior year: €1,078.2 million). In comparison with the same period last year, this corresponds to a decrease of 9.1% (prior year: -12.6%). The Eppendorf Group’s operating profit (EBIT) likewise declined, coming to €39.4 million in 2024 (prior year: €116.4 million). This equates to an EBIT margin of 4.0% (prior year: 10.8%).
Outlook for the 2025 fiscal year
For the long term, we continue to strongly anticipate sustained growth in the global life sciences industry. Nevertheless, uncertainty and volatility, as well as a range of political, economic, and geopolitical challenges will continue to shape the development of global markets in 2025. Eppendorf will keep working on the Empowering Eppendorf program while maintaining a strategic approach to cost management and demonstrating strict budget discipline over the new fiscal year.
We are witnessing a continued recovery in demand for our products and expect incoming orders to stabilize further in 2025. We foresee moderate growth within the single-digit percentage range for the entire fiscal year, compared to the previous year.
